ClinicalTrials.gg
Active, not recruitingNCT07225556Updated Jul 29, 2026

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

A Phase 1 interventional study of LY4167586 and Placebo in Overweight and Obesity, sponsored by Eli Lilly and Company. Active, not recruiting at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-29.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
84
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 118 studies in Obesity by Eli Lilly and Company — 30 open to participants now, 54 under way, 30 of them phase 3. Obesity · Eli Lilly and Company.

Planned enrollment
96th of 117
84 · median 267
Started
2025
with 27 others
Phase 1
40 of 118
8 open now
Primary completion
2026-12
later than 8 of 53 live
Registered
88th of 118
by date

Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 96th largest by planned enrollment of the 117 interventional ones that give a count, is one of 28 that started in 2025, is one of 40 in phase 1, reaches primary completion later than 8 of the 53 other live ones, and was the 88th registered.

Obesity

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

Browse Obesity studies →

Open to participants now

30 of the 118 studies in Obesity by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:

25 more — sign in →

By country, each count listing its studies:

All 30 open studies →

Who these studies take

Of the 1,346 Obesity studies recruiting now, 379 (28%) set no upper age limit and 863 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 118 studies in Obesity by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to look at how safe and well-tolerated LY4167586 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4167586 gets into the bloodstream and how long it takes the body to eliminate it following a single administration. Participation in the study will last approximately 7 months.

03

Conditions studied

  • Overweight
  • Obesity

Browse trials for

04

In context

Obesity Reclassified

11,556 studies on the registry are indexed under Obesity; 2,055 are open to participants now.

This study's planned enrollment of 84 is above the median of 67 across 9,036 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 155 are open to participants now.

Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 21 for Singapore site
  • Have a (BMI) between 27.0 kilogram per square meter (kg/m²) and 35.0 kg/m², inclusive
  • Have had a self-reported stable weight for 3 months prior to screening (less than approximately 5 percent [%] body weight change)

Exclusion criteria

Exclusion Criteria:

  • Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study drug, or of interfering with the interpretation of data.
  • Is an individual of (IOCBP)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
84 participants (estimated)

Study arms

  • Experimental
    LY4167586 (Cohorts A1 to A6)

    LY4167586 administered subcutaneously (SC)

    Drug: LY4167586

  • Placebo comparator
    Placebo (Cohorts A1 to A6)

    Placebo administered SC

    Drug: Placebo

  • Experimental
    LY4167586 (Cohort B)

    LY4167586 administered intravenously (IV)

    Drug: LY4167586

Interventions

  • DrugLY4167586

    Administered SC

  • DrugPlacebo

    Administered SC

  • DrugLY4167586

    Administered IV

07

What researchers measure

Primary outcomes

  1. Number and Incidence of Serious Adverse Events (SAEs)

    A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module

    Time frame: Baseline to study completion (up to 29 weeks)

Secondary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax)

    PK: Cmax of LY4167586

    Time frame: Predose on Day 1 through end of the Follow-up Period (Week 25)

  2. PK: Time of Maximum Drug Concentration (tmax)

    PK: tmax of LY4167586

    Time frame: Predose on Day 1 through end of the Follow-up Period (Week 25)

  3. PK: Area Under the Concentration Versus Time Curve (AUC)

    PK: AUC of LY4167586

    Time frame: Predose on Day 1 through end of the Follow-up Period (Week 25)

08

Study locations

2 sites
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 13 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2025
First posted
Nov 6, 2025
StartActual
Nov 18, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07225556
Responsible party
Sponsor
First posted
Nov 6, 2025
Start date
Nov 18, 2025
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 29, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion